L
Leila Alland
Researcher at Novartis
Publications - 25
Citations - 1820
Leila Alland is an academic researcher from Novartis. The author has contributed to research in topics: Imatinib & Imatinib mesylate. The author has an hindex of 11, co-authored 25 publications receiving 1686 citations.
Papers
More filters
Journal ArticleDOI
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
Hagop M. Kantarjian,Francis J. Giles,Lydia Wunderle,Kapil N. Bhalla,Susan O'Brien,Barbara Wassmann,Chiaki Tanaka,Paul W. Manley,Patricia Rae,William Mietlowski,Kathy Bochinski,Andreas Hochhaus,James D. Griffin,Dieter Hoelzer,Maher Albitar,Margaret Dugan,Jorge E. Cortes,Leila Alland,Oliver G. Ottmann +18 more
TL;DR: Nilotinib has a relatively favorable safety profile and is active in imatinib-resistant CML, and common adverse events were myelosuppression, transient indirect hyperbilirubinemia, and rashes.
Journal ArticleDOI
AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia
Mirna Golemović,Srdan Verstovsek,Francis J. Giles,Jorge E. Cortes,Taghi Manshouri,Paul W. Manley,Jürgen Mestan,Margaret Dugan,Leila Alland,James D. Griffin,Ralph B. Arlinghaus,Tong Sun,Hagop M. Kantarjian,Miloslav Beran +13 more
TL;DR: AMN107 inhibited autophosphorylation of Bcr-Abl kinase more effectively than imatinib in all cell lines and had similar effects on cell cycle progression and apoptotic response in these cell lines.
Journal ArticleDOI
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
Nancy L. Bartlett,Alex F. Herrera,Eva Domingo-Domenech,Amitkumar Mehta,Andres Forero-Torres,Ramón García-Sanz,Philippe Armand,Sumana Devata,Antonia Rodriguez Izquierdo,Izidore S. Lossos,Craig B. Reeder,Taimur Sher,Robert T. Chen,Sylvia Schwarz,Leila Alland,Andras Strassz,Kim Prier,Cassandra Choe-Juliak,Stephen M. Ansell +18 more
TL;DR: A Phase 1b, dose-escalation study to assess the safety and preliminary efficacy of AFM13 in combination with pembrolizumab in patients with R/R HL, which holds promise as a novel immunotherapy combination worthy of further investigation.
Journal ArticleDOI
A Phase I/II Study of AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, on a Continuous Daily Dosing Schedule in Adult Patients (pts) with Imatinib-Resistant Advanced Phase Chronic Myeloid Leukemia (CML) or Relapsed/Refractory Philadelphia Chromosome (Ph+) Acute Llymphocytic Leukemia (ALL).
Francis J. Giles,Hagop M. Kantarjian,Barbara Wassmann,J. E. Cortes,Susan O'Brien,Chiaki Tanaka,Patricia Rae,William Mietlowski,A. Romano,Leila Alland,Margaret Dugan,M. Albitar,Oliver G. Ottmann +12 more
TL;DR: The ↑ potency and broader spectrum of activity of AMN107 against Bcr-Abl, relative to IM, may result in clinical benefit for pts with CML or Ph+ ALL, and preliminary studies indicate that AMn107 has similar potency to IM against c-Kit and PDGFR-dependent cell proliferation.
Journal ArticleDOI
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant bcr-abl positive chronic myeloid leukemia (CML)
Hagop M. Kantarjian,Oliver G. Ottmann,J. E. Cortes,Barbara Wassmann,D. Jones,A. Hochhaus,Leila Alland,Margaret Dugan,M. Albitar,Francis J. Giles +9 more
TL;DR: The increased potency and broader activity of AMN107, relative to imatinib, may result in clinical benefit for patients with CML, and possible AMN-related Grade 3 or 4 hematologic adverse events were observed in the overall cohort.